Target Price | $2.85 |
Price | $14.37 |
Deviation |
80.17%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target Pharming Group N.V. - ADR 2026 .
The average Pharming Group N.V. - ADR target price is $2.85.
This is
80.17%
register free of charge
$33.88
135.68%
register free of charge
$1.65
88.55%
register free of charge
|
|
A rating was issued by 13 analysts: 12 Analysts recommend Pharming Group N.V. - ADR to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Pharming Group N.V. - ADR stock has an average upside potential 2026 of
80.17%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 297.20 | 349.81 |
21.15% | 17.70% | |
EBITDA Margin | 2.51% | 4.23% |
157.26% | 68.75% | |
Net Margin | -3.98% | 7.36% |
7.36% | 284.75% |
8 Analysts have issued a sales forecast Pharming Group N.V. - ADR 2025 . The average Pharming Group N.V. - ADR sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Pharming Group N.V. - ADR EBITDA forecast 2025. The average Pharming Group N.V. - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Pharming Group N.V. - ADR Analysts have issued a net profit forecast 2025. The average Pharming Group N.V. - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.02 | 0.04 |
0.00% | 300.00% | |
P/E | 382.56 | |
EV/Sales | 2.79 |
8 Analysts have issued a Pharming Group N.V. - ADR forecast for earnings per share. The average Pharming Group N.V. - ADR EPS is
This results in the following potential growth metrics and future valuations:
Pharming Group N.V. - ADR...
Analyst | Rating | Action | Date |
---|---|---|---|
FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Sep 03 2025 |
JEFFERIES |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Aug 21 2025 |
PORTZAMPARC BNP PARIBAS |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Jun 30 2025 |
OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Jun 29 2025 |
JEFFERIES |
Locked
➜
Locked
|
Locked | May 08 2025 |
Analyst Rating | Date |
---|---|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Sep 03 2025 |
Locked
JEFFERIES:
Locked
➜
Locked
|
Aug 29 2025 |
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Aug 21 2025 |
Locked
PORTZAMPARC BNP PARIBAS:
Locked
➜
Locked
|
Aug 05 2025 |
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Jun 30 2025 |
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Jun 29 2025 |
Locked
JEFFERIES:
Locked
➜
Locked
|
May 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.